Suppr超能文献

使用骨架环化和环扫描将蛋白质活性区域转化为拟肽治疗先导物——自己动手!

Conversion of Protein Active Regions into Peptidomimetic Therapeutic Leads Using Backbone Cyclization and Cycloscan - How to Do it Yourself!

机构信息

Stanford Immunology Program, School of Medicine, Stanford University, 269 Campus drive, Stanford CA 94305-5174, United States.

Department of Chemistry, University of Nevada, Reno, 1664 North Virginia Street, NV 89557, United States.

出版信息

Curr Top Med Chem. 2018;18(7):556-565. doi: 10.2174/1568026618666180518094322.

Abstract

Protein-protein Interactions (PPIs) are particularly important for controlling both physiologic and pathologic biological processes but are difficult to target due to their large and/or shallow interaction surfaces unsuitable for small molecules. Linear peptides found in nature interact with some PPIs, and protein active regions can be used to design synthetic peptide compounds for inhibition of PPIs. However, linear peptides are limited therapeutically by poor metabolic and conformational stability, which can compromise their bioactivity and half-life. Cyclic peptidomimetics (modified peptides) can be used to overcome these challenges because they are more resistant to metabolic degradation and can be engineered to adopt desired conformations. Backbone cyclization is a strategy that we developed to improve drug-like properties of linear peptide leads without jeopardizing the integrity of functionally relevant side-chains. Here, we provide the first description of an entire approach for developing backbone cyclized peptide compounds, based upon two straightforward 'ABC' and 'DEF' processes. We present practical examples throughout our discussion of revealing active regions important for PPIs and identifying critical pharmacophores, as well as developing backbone cyclized peptide libraries and screening them using cycloscan. Finally, we review the impact of these advances and provide a summary of current ongoing work in the field.

摘要

蛋白质-蛋白质相互作用 (PPIs) 对控制生理和病理生物过程特别重要,但由于其较大和/或较浅的相互作用表面不适合小分子,因此难以成为靶点。天然存在的线性肽与一些 PPI 相互作用,并且可以使用蛋白质活性区域来设计用于抑制 PPI 的合成肽化合物。然而,线性肽在治疗上受到代谢和构象稳定性差的限制,这可能会影响它们的生物活性和半衰期。环肽类似物(修饰肽)可用于克服这些挑战,因为它们对代谢降解的抵抗力更强,并且可以设计成采用所需的构象。骨架环化是我们开发的一种策略,用于提高线性肽先导物的药物样特性,而不会危及功能相关侧链的完整性。在这里,我们提供了一种基于两个简单的“ABC”和“DEF”过程开发骨架环化肽化合物的完整方法的首次描述。在讨论揭示对 PPI 重要的活性区域和确定关键药效团以及开发骨架环化肽文库并使用 cycloscan 对其进行筛选时,我们提供了实际示例。最后,我们回顾了这些进展的影响,并总结了该领域当前正在进行的工作。

相似文献

2
Backbone-Cyclized Peptides: A Critical Review.骨干环肽:综述
Curr Top Med Chem. 2018;18(7):526-555. doi: 10.2174/1568026618666180518092333.
10
γ-AApeptides: Design, Structure, and Applications.γ-氨基酸肽:设计、结构与应用
Acc Chem Res. 2016 Mar 15;49(3):428-41. doi: 10.1021/acs.accounts.5b00492. Epub 2016 Feb 22.

引用本文的文献

3
Developing a peptide to disrupt cohesin head domain interactions.开发一种肽以破坏黏连蛋白头部结构域的相互作用。
iScience. 2023 Jul 28;26(9):107498. doi: 10.1016/j.isci.2023.107498. eCollection 2023 Sep 15.
6
Towards rational computational peptide design.迈向合理的计算肽设计。
Front Bioinform. 2022 Oct 21;2:1046493. doi: 10.3389/fbinf.2022.1046493. eCollection 2022.
9
Cyclizing Painkillers: Development of Backbone-Cyclic TAPS Analogs.环化止痛药:主链环化TAPS类似物的开发
Front Chem. 2020 Nov 12;8:532577. doi: 10.3389/fchem.2020.532577. eCollection 2020.

本文引用的文献

1
3
Peptide therapeutics: current status and future directions.肽类治疗药物:现状与未来方向。
Drug Discov Today. 2015 Jan;20(1):122-8. doi: 10.1016/j.drudis.2014.10.003. Epub 2014 Oct 17.
7
Improvement of drug-like properties of peptides: the somatostatin paradigm.改善肽类药物的特性:生长抑素范例。
Expert Opin Drug Discov. 2010 Jul;5(7):655-71. doi: 10.1517/17460441.2010.493935. Epub 2010 Jun 3.
9
Backbone cyclic peptide inhibitors of protein kinase B (PKB/Akt).蛋白激酶 B(PKB/Akt)的骨干环肽抑制剂。
J Med Chem. 2011 Jul 28;54(14):5154-64. doi: 10.1021/jm2003969. Epub 2011 Jun 22.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验